Table 3.
Characteristics of patients receiving palliative radiotherapy for gynecologic cancers (n = 40).
| % | n | |
|---|---|---|
| Age group | ||
| < 30 | 2 | 1 |
| 30-39 | – | – |
| 40-49 | 12 | 5 |
| 50-59 | 35 | 14 |
| 60-69 | 28 | 11 |
| ≥ 70 | 23 | 9 |
| Cancer site | ||
| Corpus uteri | 20 | 8 |
| Cervix | 10 | 4 |
| Ovary | 57 | 23 |
| Vulva | 10 | 4 |
| Vagina | 3 | 1 |
| Time of metastasis | ||
| At first diagnosis | 15 | 6 |
| At follow-up | 85 | 34 |
| Baseline FIGO stage | ||
| I | 5 | 2 |
| II | 10 | 4 |
| III | 70 | 28 |
| IV | 15 | 6 |
| Baseline SEER stage | ||
| Localized | 5 | 2 |
| Regional | 80 | 32 |
| Distant | 15 | 6 |
| Radiotherapy sites | ||
| Brain | 30 | 12 |
| Bone | 27 | 11 |
| Lymph node | 17 | 7 |
| Vaginal cuff | 13 | 5 |
| Whole pelvic | 10 | 4 |
| Whole abdomen | 3 | 1 |
| Reasons for palliation | ||
| Pain | 42 | 17 |
| Neurologic symptom | 30 | 12 |
| Bleeding | 28 | 11 |
FIGO, International Federation of Gynecology and Obstetrics; SEER, Surveillance, Epidemiology, and End Results (National Cancer Institute, United States of America).